Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0V2KR
|
||||
| Former ID |
DIB007182
|
||||
| Drug Name |
Yttrium (90Y) clivatuzumab tetraxetan
|
||||
| Synonyms |
PAM4 mAb; Yttrium Y 90 clivatuzumab tetraxetan; Anti-MUC1 PAM4 monoclonal antibody; Clivatuzumab tetraxetan-[90Y]; HPAM4-Cide; IMMU-107; PAM-4; PAM4-Y-90; Yttrium-90-hPAM4; 90Y-clivatuzumab tetraxetan; 90Y-hPAM4
|
||||
| Drug Type |
Antibody
|
||||
| Company |
Immunomedics; Garden State Cancer Center; Immunomedics
|
||||
| Target and Pathway | |||||
| Target(s) | Mucin 1 | Target Info | [551008] | ||
| WikiPathways | Hematopoietic Stem Cell Differentiation | ||||
| References | |||||
| Ref 524457 | ClinicalTrials.gov (NCT01956812) Phase 3 Trial of 90Y-Clivatuzumab Tetraxetan & Gemcitabine vs Placebo & Gemcitabine in Metastatic Pancreatic Cancer. U.S. National Institutes of Health. | ||||
| Ref 542962 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8087). | ||||